Capoxigem apricoxib: Completed Phase II enrollment

Tragara completed enrollment of 128 patients in the double-blind, placebo-controlled Phase II APRiCOT-L trial evaluating 400 mg/day oral Capoigem apricoxib plus Tarceva erlotinib. Tarceva is marketed...